FAIRFIELD, CT, June 03, 2013 (Press-News.org) In their May 17th "Digital Crave" shopping blog, Yahoo! included the new ThiPad thigh-mounted tablet stand in a piece titled "The Worst iPad Accessories--Ever."
"And they did us a favor," says Jerry McTigue, creator of the ThiPad. "Because the hundreds of readers who went to the ThiPad.com website to see just how bad a product it was, actually discovered how good it was. And they started buying it."
McTigue believes that if the ThiPad can gain converts with horrible publicity like that, there's no telling what it would do if given a fair evaluation. He maintains that the so-called reporter never bothered to obtain a sample of the product and try it out. "Rather, he based his snide judgements on website images and a pre-prejudiced need to round up targets for a snark attack," says McTigue. "This is the kind of shoot-from-the-hip, junk journalism that's rampant on the Internet, intended to throw red meat to ridicule-hungry trolls. Yet it can be potentially devastating to people making an honest living creating products that deliver real value to users."
The ThiPad Hands-Free Tablet Stand straps securely to the leg just above the knee, with a non-slip surface that snugly holds any-sized tablet computer, including iPads, Kindles, Nooks, Androids, smartphones, and other mobile devices, in their cases or out. It provides hours of comfortable viewing, working, typing, playing games, or practicing with a musical instrument, without tying up the hands or tiring out the arms.
McTigue invites reputable journalists and media organizations to request a review sample of the product so they can give it a fair and impartial test run. "Then they can love it, hate it, pan it, or praise it, as they see fit," he says. "But we think they'll be surprised at how securely the new ThiPad fits and how beautifully it performs."
To request a review sample, contact inquiry@thipad.com or 203-254-7789. To learn more visit http://thipad.com.
ThiPad.com is the creator and manufacturer of the new ThiPad Hands-Free Tablet Stand.
"Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet Stand
Included among the "Worst Ever" iPad accessories by a Yahoo! shopping blog, the ThiPad Hands-Free Tablet Stand actually experienced a sharp spike in sales when intrigued readers flocked to the ThiPad.com site.
2013-06-03
ELSE PRESS RELEASES FROM THIS DATE:
Some patients with treatment-resistant colorectal cancers may have a new option
2013-06-02
PHILADELPHIA — A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs.
The MET gene is known to be amplified in about ...
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
2013-06-02
Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.
Chicago, Illinois—GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is ...
New cancer drug shows promise for treating advanced melanoma
2013-06-02
Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.
The results were presented at the 2013 meeting of the American Society of Clinical Oncology today in Chicago by Dr. Antoni Ribas, professor of medicine in the UCLA division of hematology-oncology, who led the research. Following Ribas' presentation, the study was published online ahead of press in the New England Journal of Medicine. ...
Test helps target glioblastoma patients most likely to benefit from bevacizumab
2013-06-02
CHICAGO, IL – A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center.
The results of the study were presented today at the annual meeting of the American Society of Clinical Oncology.
This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma. Half of the participants ...
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
2013-06-02
CHICAGO, JUNE 2, 2013 — The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Several patients experienced tumor shrinkage of more than 80 percent within ...
Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
2013-06-02
Chicago, IL – The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of Neuro-Oncology.
Glioblastoma is both the most common and lethal form of brain ...
US oncologists report high career satisfaction, yet many suffer symptoms of burnout
2013-06-02
CHICAGO -- Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.
"Oncology can be a tremendously rewarding area of medicine, but caring for patients with cancer is also demanding and stressful," says lead author Tait Shanafelt, M.D., a Mayo Clinic hematologist/oncologist. "Oncologists work long hours, supervise the administration of highly toxic ...
Abnormalities in HER2 gene found in wide variety of advanced cancers
2013-06-02
(CHICAGO) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.
The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these tumors might benefit from the three anti-HER2 therapies now in clinical use.
"No ...
Therapy that heats and destroys bone tumors eases patients' pain
2013-06-02
(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, ...
Targeted therapy sorafenib shows success in advanced differentiated thyroid cancer patients
2013-06-02
CHICAGO – The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4).
If approved for use in thyroid cancer patients by the Food and Drug Administration, sorafenib (Nexavar), a kinase inhibitor that mediates tumor ...
LAST 30 PRESS RELEASES:
Why chronic pain lasts longer in women: Immune cells offer clues
Toxic exposure creates epigenetic disease risk over 20 generations
More time spent on social media linked to steroid use intentions among boys and men
New study suggests a “kick it while it’s down” approach to cancer treatment could improve cure rates
Milken Institute, Ann Theodore Foundation launch new grant to support clinical trial for potential sarcoidosis treatment
New strategies boost effectiveness of CAR-NK therapy against cancer
Study: Adolescent cannabis use linked to doubling risk of psychotic and bipolar disorders
Invisible harms: drug-related deaths spike after hurricanes and tropical storms
Adolescent cannabis use and risk of psychotic, bipolar, depressive, and anxiety disorders
Anxiety, depression, and care barriers in adults with intellectual and developmental disabilities
Study: Anxiety, gloom often accompany intellectual deficits
Massage Therapy Foundation awards $300,000 research grant to the University of Denver
Gastrointestinal toxicity linked to targeted cancer therapies in the United States
Countdown to the Bial Award in Biomedicine 2025
Blood marker from dementia research could help track aging across the animal world
Birds change altitude to survive epic journeys across deserts and seas
Here's why you need a backup for the map on your phone
ACS Central Science | Researchers from Insilico Medicine and Lilly publish foundational vision for fully autonomous “Prompt-to-Drug” pharmaceutical R&D
Increasing the number of coronary interventions in patients with acute myocardial infarction does not appear to reduce death rates
Tackling uplift resistance in tall infrastructures sustainably
Novel wireless origami-inspired smart cushioning device for safer logistics
Hidden genetic mismatch, which triples the risk of a life-threatening immune attack after cord blood transplantation
Physical function is a crucial predictor of survival after heart failure
Striking genomic architecture discovered in embryonic reproductive cells before they start developing into sperm and eggs
Screening improves early detection of colorectal cancer
New data on spontaneous coronary artery dissection (SCAD) – a common cause of heart attacks in younger women
How root growth is stimulated by nitrate: Researchers decipher signalling chain
Scientists reveal our best- and worst-case scenarios for a warming Antarctica
Cleaner fish show intelligence typical of mammals
AABNet and partners launch landmark guide on the conservation of African livestock genetic resources and sustainable breeding strategies
[Press-News.org] "Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet StandIncluded among the "Worst Ever" iPad accessories by a Yahoo! shopping blog, the ThiPad Hands-Free Tablet Stand actually experienced a sharp spike in sales when intrigued readers flocked to the ThiPad.com site.